Impact of Untreated Psychosis Duration on Short-Term Outcomes in Initial Episodes of Schizophrenia - Scorecard - MDSpire

Impact of Untreated Psychosis Duration on Short-Term Outcomes in Initial Episodes of Schizophrenia

  • By

  • Dinghui Wang

  • Kaiguo Zhang

  • Zhi Xun Zhang

  • Qingqing Zhang

  • Min Liu

  • Yanhong Huang

  • Zhenqiang Xu

  • April 29, 2026

  • 0 min

Share

Clinical Scorecard: Impact of Untreated Psychosis Duration on Short-Term Outcomes in Initial Episodes of Schizophrenia

At a Glance

CategoryDetail
ConditionSchizophrenia
Key MechanismsDuration of untreated psychosis (DUP) influences prognosis and symptom improvement.
Target PopulationFirst-episode schizophrenia patients hospitalized at Shantou University Mental Health Center.
Care SettingInpatient psychiatric care

Key Highlights

  • Shorter DUP (≤26 weeks) is associated with greater symptom improvement compared to longer DUP (>26 weeks).
  • Mean BPRS improvement was significantly higher in the short DUP group (11.50 points) after matching.
  • Higher baseline BPRS scores correlate with greater symptom improvement.
  • The adverse effects of long DUP are more pronounced in patients with higher baseline symptom severity.
  • DUP serves as a clinically useful prognostic indicator for early intervention.

Guideline-Based Recommendations

Diagnosis

  • Assess duration of untreated psychosis as part of the diagnostic evaluation.

Management

  • Implement early intervention strategies to reduce DUP and improve outcomes.

Monitoring & Follow-up

  • Regularly evaluate symptom severity using standardized scales like BPRS.

Risks

  • Longer DUP is associated with persistent symptoms, lower remission rates, and increased risk of suicide attempts.

Patient & Prescribing Data

First-episode schizophrenia patients hospitalized from 2015 to 2019.

Early treatment initiation is crucial for improving short-term outcomes.

Clinical Best Practices

  • Prioritize early detection and treatment of psychosis to minimize DUP.
  • Utilize standardized assessment tools to evaluate symptom severity and treatment response.

References

Original Source(s)

Related Content